

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0051-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

### Complete if Known

<b>Application Number</b>	09/982,351
<b>Filing Date</b>	October 18, 2001
<b>First Named Inventor</b>	Aleem Gangjee
<b>Group Art Unit</b>	1615
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	049450-00170

APR 03 2002  
 CENTER 1600/2900

#5

RECEIVED

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "JC67" is at the top right, "FEB 28 2002" is in the center, and "PATENT &amp; TRADEMARKS OFFICE" is at the bottom.

**COPY OF PAPERS  
ORIGINALLY FILED**

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T<sup>2</sup>

W3	A	CHERRINGTON ET AL., "New Paradigms for the Treatment of Cancer: The Role of Anti-Angiogenesis Agents", Advances in Cancer Research, 2000, pp. 1-38
W3	B	TRAXLER ET AL., "Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors", Pharmacol. Ther. Vol. 82, Nos. 2-3, pp. 195-206, 1999
W3	C	SUN ET AL., "Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors", Reviews, DDT Vol. 5 No. 8 August 2000, pp. 344-353

RECEIVED

MAR -4 2002

~~TECH CENTER 1600/2900~~

Examiner  
Signature

Mark Beer

Date Considered

7-11-02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+